Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
dopamine
Biotech
Emalex eyes potential Tourette approval after phase 3 win
When continued on ecopipam, 41.9% of children had their symptoms relapse, significantly lower than the 68.1% rate seen in children given placebo.
Darren Incorvaia
Feb 25, 2025 1:18pm
Autoreceptor absence fuels dopamine dysfunction in schizophrenia
Nov 1, 2022 11:00am
Dopamine's dreamy role: a potential new sleep drug target
Mar 8, 2022 7:35am
Repurposing Novartis’ cancer drug Tasigna in Parkinson’s
Mar 13, 2019 11:23am
Transforming mature neurons into dopamine factories
Oct 11, 2018 2:00pm